Home Technology Nvidia Suspends AI Chip Deliveries to China as Export Uncertainty Grows
TechnologyBusinessWorld

Nvidia Suspends AI Chip Deliveries to China as Export Uncertainty Grows

Share
Share

Nvidia has halted shipments of its approved AI processors to China, adding fresh pressure to its operations in a market facing growing technology and trade restrictions.

The company’s interim CEO, Colette Kress, confirmed that Nvidia generated $2.4 billion from licensed Hopper-generation chip sales to China in the last quarter. However, the company has excluded further Chinese shipments from its latest financial outlook.

The decision affects Nvidia’s H200 processors, which are widely used for training and running advanced artificial intelligence models.

Although the US government eased export restrictions in January 2026, allowing selected Chinese technology companies such as Alibaba, Tencent and ByteDance to purchase the chips, Beijing has also introduced restrictions on their imports.

The developments reflect the continuing challenges facing the global semiconductor industry as both countries seek greater control over advanced AI technology.

Nvidia has yet to explain the reason for the suspension or indicate when shipments could resume.

See also  D’Tigers Name 12 Man Squad for Crucial World Cup Qualifiers in Tunisia
Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Digital Payment Use Rises Among Nigerians Despite Fraud Experiences, Report Reveals

The 2026 State of Inclusive Instant Payment Systems in Africa (SIIPS) report,...

Banking Sell-Off Drags NGX Down as Investors Lose N406 Billion

Investors in Nigeria's stock market lost N406.34 billion in market value on...

African Businesses Face Shutdowns, Liquidation and Licence Revocations in Third Quarter of 2026

Several businesses across Africa faced shutdowns, insolvency proceedings and regulatory action in...

New pancreatic cancer pill raises hope as tumours disappear in early trials

A new daily pill, daraxonrasib, has shown promising results in early clinical...